ABBV 65.95 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 66.15 Closing the day 09:45 at 65.95 -0.10 -0.15% With a day low of 65.56 and a total volume of 346,253.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 38.41 (+0.09), VIPS: 21.12 (-2.59), CNX: 40.19 (-0.42), MON: 118.93 (-0.40), DAL: 44.83 (+0.04), CHTR: 155.44 (+0.32), ESNT: 22.48 (-0.18), CNP: 24.51 (-0.08), INTC: 34.75 (+0.04), GOOG: 531.76 (-3.27), CTXS: 64.42 (-0.64), MSI: 65.86 (-0.14), EEM: 41.09 (-0.13), SPY: 205.05 (-0.50), AAL: 45.18 (+0.13), ABBV: 65.94 (-0.11), GDX: 20.20 (-0.10), MSFT: 48.27 (-0.47), SYK: 89.87 (-0.29), PSX: 74.74 (+0.78), FB: 74.26 (-0.08), HAL: 48.77 (+0.23), PLCM: 13.12 (-0.08), LVLT: 49.05 (-0.41), TEVA: 57.40 (+0.17), AIG: 54.03 (+0.14), IWM: 115.63 (-0.76), DOW: 52.34 (+0.27), LUK: 24.43 (-0.10), VRX: 141.15 (-0.79), LBTYK: 45.29 (-0.21), CLI: 19.17 (-0.11), CZR: 14.92 (-0.40), CACQ: 10.12 (-0.22), EGN: 66.38 (-0.18), TIBX: 23.68 (unch), LBTYA: 46.44 (-0.28), ALLE: 53.73 (-0.14), SEMG: 81.08 (+0.71), AGRO: 9.27 (+0.09), GOOGL: 541.44 (-3.07), NICE: 46.18 (+0.02), AAPL: 114.72 (-0.75), WAG: 67.63 (-0.43), XLE: 86.03 (+0.20), WNR: 41.72 (+0.49), PVA: 8.24 (-0.11), DISH: 71.10 (+3.25), EQT: 94.75 (+1.17), LORL: 73.95 (-0.31), BIDU: 244.46 (+1.71), QQQ: 103.24 (-0.44), GM: 32.11 (-0.16), HUB.B: 109.01 (-0.74), BABA: 108.77 (-2.04)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 265.07 (-4.53), CLDX: 18.19 (+0.47), ABBV: 65.94 (-0.11)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 212.24 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 212.24 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20), NVS: 95.62 (+0.04)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), MRK: 59.47 (-0.42), AMGN: 161.11 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20), CELG: 106.47 (-0.31)
Enanta And AbbVie's ABT-450 Likely To Receive FDA Approval
Beacon VP Investments - at Seeking Alpha - Tue Nov 18, 10:13AM CST
ABBV: 65.94 (-0.11), ENTA: 43.68 (-0.02)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 102.17 (-1.54), ABBV: 65.94 (-0.11)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 212.24 (-1.13), MRK: 59.47 (-0.42), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.67 (-0.07), ABBV: 65.94 (-0.11), ENTA: 43.68 (-0.02), NVS: 95.62 (+0.04)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), GLD: 115.15 (+0.10), ABBV: 65.94 (-0.11), TWTR: 40.15 (-0.46), NVS: 95.62 (+0.04)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 209.75 (-0.25), PFE: 30.50 (-0.09), MRK: 59.47 (-0.42), AZN: 74.59 (+0.61), ABBV: 65.94 (-0.11)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), ABBV: 65.94 (-0.11), CELG: 106.47 (-0.31)
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Mon Nov 17, 6:00AM CST
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. GMT (3:20 a.m. Central time.)
ABBV: 65.94 (-0.11)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 74.59 (+0.61), LLY: 67.16 (-0.62), ABBV: 65.94 (-0.11), GSK: 46.15 (-0.13), SNY: 48.28 (-0.08), NVS: 95.62 (+0.04)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.50 (-0.09), AZN: 74.59 (+0.61), ABBV: 65.94 (-0.11)
7 Aristocrat Dividend Dogs Hit 5% To 12.75% November Upsides
Fredrik Arnold - at Seeking Alpha - Fri Nov 14, 5:10PM CST
KO: 44.00 (+0.47), HCP: 43.90 (-0.14), CLX: 100.34 (-0.43), GPC: 100.30 (+0.18), TROW: 81.83 (-0.19), NUE: 53.62 (-0.74), ED: 62.34 (-0.69), SYY: 39.11 (-0.03), LEG: 40.92 (-0.13), EMR: 63.97 (-0.07), XOM: 94.83 (-0.04), PEP: 98.05 (+0.11), T: 35.45 (-0.27), CINF: 50.81 (-0.15), ADP: 84.40 (-0.35), TGT: 70.85 (+3.34), MCD: 96.80 (+0.39), ABBV: 65.94 (-0.11), CVX: 115.65 (+0.18), AFL: 59.08 (-0.02), CL: 67.91 (-0.06)
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
PR Newswire - Fri Nov 14, 3:48PM CST
AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.
ABBV: 65.94 (-0.11)
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 14, 8:00AM CST
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 326.57 (+1.64), FB: 74.27 (-0.07), ABBV: 65.94 (-0.11), GOOGL: 541.44 (-3.07), GOOG: 531.76 (-3.27)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.32 (-0.51), GILD: 102.15 (-1.56), MRK: 59.47 (-0.42), ABBV: 65.94 (-0.11)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 102.15 (-1.56), ABBV: 65.94 (-0.11)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Tracking George Soros's Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Wed Nov 19, 4:48AM CST
HLF: 38.41 (+0.09), VIPS: 21.12 (-2.59), CNX: 40.19 (-0.42), MON: 118.93 (-0.40), DAL: 44.83 (+0.04), CHTR: 155.44 (+0.32), ESNT: 22.48 (-0.18), CNP: 24.51 (-0.08), INTC: 34.75 (+0.04), GOOG: 531.76 (-3.27), CTXS: 64.42 (-0.64), MSI: 65.86 (-0.14), EEM: 41.09 (-0.13), SPY: 205.05 (-0.50), AAL: 45.18 (+0.13), ABBV: 65.94 (-0.11), GDX: 20.20 (-0.10), MSFT: 48.27 (-0.47), SYK: 89.87 (-0.29), PSX: 74.74 (+0.78), FB: 74.26 (-0.08), HAL: 48.77 (+0.23), PLCM: 13.12 (-0.08), LVLT: 49.05 (-0.41), TEVA: 57.40 (+0.17), AIG: 54.03 (+0.14), IWM: 115.63 (-0.76), DOW: 52.34 (+0.27), LUK: 24.43 (-0.10), VRX: 141.15 (-0.79), LBTYK: 45.29 (-0.21), CLI: 19.17 (-0.11), CZR: 14.92 (-0.40), CACQ: 10.12 (-0.22), EGN: 66.38 (-0.18), TIBX: 23.68 (unch), LBTYA: 46.44 (-0.28), ALLE: 53.73 (-0.14), SEMG: 81.08 (+0.71), AGRO: 9.27 (+0.09), GOOGL: 541.44 (-3.07), NICE: 46.18 (+0.02), AAPL: 114.72 (-0.75), WAG: 67.63 (-0.43), XLE: 86.03 (+0.20), WNR: 41.72 (+0.49), PVA: 8.24 (-0.11), DISH: 71.10 (+3.25), EQT: 94.75 (+1.17), LORL: 73.95 (-0.31), BIDU: 244.46 (+1.71), QQQ: 103.24 (-0.44), GM: 32.11 (-0.16), HUB.B: 109.01 (-0.74), BABA: 108.77 (-2.04)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 265.07 (-4.53), CLDX: 18.19 (+0.47), ABBV: 65.94 (-0.11)
Roche's (RHHBY) Avastin Label Expansion Approved by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:45PM CST
Roche (RHHBY) announced that the FDA has approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
AGN: 212.24 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20)
Novartis Presents Data on Heart Failure Candidate LCZ696 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:44PM CST
Novartis (NVS) announced new data on pipeline candidate, LCZ696, from the phase III study, PARADIGM-HF.
AGN: 212.24 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20), NVS: 95.62 (+0.04)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), MRK: 59.47 (-0.42), AMGN: 161.11 (-1.13), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20), CELG: 106.47 (-0.31)
Enanta And AbbVie's ABT-450 Likely To Receive FDA Approval
Beacon VP Investments - at Seeking Alpha - Tue Nov 18, 10:13AM CST
ABBV: 65.94 (-0.11), ENTA: 43.68 (-0.02)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 102.17 (-1.54), ABBV: 65.94 (-0.11)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 212.24 (-1.13), MRK: 59.47 (-0.42), ABBV: 65.94 (-0.11), BMY: 58.50 (-0.20)
Will IPOs WhiteWave, Enanta Surpass Buy Points?
at Investor's Business Daily - Mon Nov 17, 5:27PM CST
With the market in a confirmed uptrend, many IPO Leaders are extended beyond their buy points. But a few, including WhiteWave Foods (WWAV) and Enanta Pharmaceuticals (ENTA), are still within striking distance. WhiteWave has been trading near a 37.25...
WWAV: 36.67 (-0.07), ABBV: 65.94 (-0.11), ENTA: 43.68 (-0.02), NVS: 95.62 (+0.04)
Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), GLD: 115.15 (+0.10), ABBV: 65.94 (-0.11), TWTR: 40.15 (-0.46), NVS: 95.62 (+0.04)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 209.75 (-0.25), PFE: 30.50 (-0.09), MRK: 59.47 (-0.42), AZN: 74.59 (+0.61), ABBV: 65.94 (-0.11)
Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.32 (-0.51), GILD: 102.17 (-1.54), ABBV: 65.94 (-0.11), CELG: 106.47 (-0.31)
AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Mon Nov 17, 6:00AM CST
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. GMT (3:20 a.m. Central time.)
ABBV: 65.94 (-0.11)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 74.59 (+0.61), LLY: 67.16 (-0.62), ABBV: 65.94 (-0.11), GSK: 46.15 (-0.13), SNY: 48.28 (-0.08), NVS: 95.62 (+0.04)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.50 (-0.09), AZN: 74.59 (+0.61), ABBV: 65.94 (-0.11)
7 Aristocrat Dividend Dogs Hit 5% To 12.75% November Upsides
Fredrik Arnold - at Seeking Alpha - Fri Nov 14, 5:10PM CST
KO: 44.00 (+0.47), HCP: 43.90 (-0.14), CLX: 100.34 (-0.43), GPC: 100.30 (+0.18), TROW: 81.83 (-0.19), NUE: 53.62 (-0.74), ED: 62.34 (-0.69), SYY: 39.11 (-0.03), LEG: 40.92 (-0.13), EMR: 63.97 (-0.07), XOM: 94.83 (-0.04), PEP: 98.05 (+0.11), T: 35.45 (-0.27), CINF: 50.81 (-0.15), ADP: 84.40 (-0.35), TGT: 70.85 (+3.34), MCD: 96.80 (+0.39), ABBV: 65.94 (-0.11), CVX: 115.65 (+0.18), AFL: 59.08 (-0.02), CL: 67.91 (-0.06)
AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
PR Newswire - Fri Nov 14, 3:48PM CST
AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.
ABBV: 65.94 (-0.11)
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 14, 8:00AM CST
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 326.57 (+1.64), FB: 74.27 (-0.07), ABBV: 65.94 (-0.11), GOOGL: 541.44 (-3.07), GOOG: 531.76 (-3.27)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.32 (-0.51), GILD: 102.15 (-1.56), MRK: 59.47 (-0.42), ABBV: 65.94 (-0.11)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 102.15 (-1.56), ABBV: 65.94 (-0.11)
![Perspective Therapeutics Enhances [212Pb]VMT01 for Melanoma Treatment](/images/blog/ihnews-Perspective%20Therapeutics%20Enhances%20%5B212Pb%5DVMT01%20for%20Melanoma%20Treatment.jpg)
